- Home
- FRME vs BHVN Comparison
FRME vs BHVN Comparison
Compare FRME & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRME
- BHVN
- Stock Information
- Founded
- FRME 1893
- BHVN 2013
- Country
- FRME United States
- BHVN United States
- Employees
- FRME N/A
- BHVN N/A
- Industry
- FRME Major Banks
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- FRME Finance
- BHVN Health Care
- Exchange
- FRME Nasdaq
- BHVN Nasdaq
- Market Cap
- FRME 2.1B
- BHVN 1.9B
- IPO Year
- FRME N/A
- BHVN 2017
- Fundamental
- Price
- FRME $37.46
- BHVN $14.82
- Analyst Decision
- FRME Buy
- BHVN Strong Buy
- Analyst Count
- FRME 4
- BHVN 14
- Target Price
- FRME $45.50
- BHVN $59.85
- AVG Volume (30 Days)
- FRME 211.5K
- BHVN 2.4M
- Earning Date
- FRME 07-24-2025
- BHVN 05-12-2025
- Dividend Yield
- FRME 3.82%
- BHVN N/A
- EPS Growth
- FRME 2.61
- BHVN N/A
- EPS
- FRME 3.55
- BHVN N/A
- Revenue
- FRME $615,411,000.00
- BHVN N/A
- Revenue This Year
- FRME $15.14
- BHVN N/A
- Revenue Next Year
- FRME $5.03
- BHVN $65.26
- P/E Ratio
- FRME $10.62
- BHVN N/A
- Revenue Growth
- FRME N/A
- BHVN N/A
- 52 Week Low
- FRME $30.55
- BHVN $14.33
- 52 Week High
- FRME $46.13
- BHVN $55.70
- Technical
- Relative Strength Index (RSI)
- FRME 48.72
- BHVN 31.09
- Support Level
- FRME $36.92
- BHVN $14.86
- Resistance Level
- FRME $38.48
- BHVN $15.94
- Average True Range (ATR)
- FRME 0.98
- BHVN 1.27
- MACD
- FRME -0.09
- BHVN -0.16
- Stochastic Oscillator
- FRME 27.37
- BHVN 3.31
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.